Dreismann Heinrich 4

What Happened Heinrich Dreismann, a director of Mainz Biomed N.V. (MYNZ), received an award of 45,000 restricted common shares on 2026-02-13. The shares were granted at $0.00 per share (no cash consideration), under the company's 2025 Omnibus Incentive Plan and reported on a Form 4 filed 2026-02-19.

Key Details

• Transaction date: 2026-02-13; Form 4 filed: 2026-02-19.
• Transaction type/code: A — Award/Grant of restricted shares.
• Shares granted: 45,000 restricted shares; per-share cost reported as $0.00 (no cash paid).
• Post-transaction holdings: Not specified in the provided Form 4.
• Footnotes: F1 — grant under 2025 Omnibus Incentive Plan, no cash consideration; F2 — 19,700 employee stock options were granted and previously reported on a Form 3 filed 2026-01-26.
• Timeliness: The Form 4 was filed six days after the transaction date; this appears later than the typical two-business-day filing requirement for Form 4s.

Context This was a grant of restricted shares (an award), not an open-market purchase or sale, so it reflects compensation/long-term incentive rather than a direct market signal. Such awards are common for directors and management as part of compensation plans. The filing notes a separate earlier disclosure of 19,700 employee stock options (Form 3, 2026-01-26).